Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients? (Q37534534)

20 August 2017

1 reference

title

Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients? (English)

1 reference

20 August 2017

1 reference

4

Riikka Räty

0 references

Christian Geisler

1

object named as

Christian Geisler

0 references

Arne Kolstad

2

object named as

Arne Kolstad

1 reference

20 August 2017

Christian Geisler

1

1 reference

20 August 2017

Anna Laurell

3

1 reference

20 August 2017

Riikka Räty

4

1 reference

20 August 2017

Nordic Lymphoma Group

5

1 reference

20 August 2017

Mantle Cell Lymphoma Subcommittee

6

1 reference

20 August 2017

1 August 2009

1 reference

20 August 2017

1 reference

20 August 2017

50

1 reference

20 August 2017

1249-1256

1 reference

20 August 2017

8

1 reference

Outcome of deferred initial therapy in mantle-cell lymphoma

20 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903040030

10.1080/10428190903040030

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference